Protein kinase CK2 is widely expressed in follicular, Burkitt and diffuse large B-cell lymphomas and propels malignant B-cell growth

• DOI: 10.18632/oncotarget.3446
• Publication Date: 2015-09-15T07:55:06Z
• Authors: Marco Pizzi; Francesco Piazza; Claudio Agostinelli; Fabio Fuligni; Pietro Benvenuti; Elisa Mandato; Alessandro Casellato; Massimo Rugge; Gianpietro Semenzato; Stefano A. Pileri
• Keywords: Follicular lymphoma; Hematology; Hematopathology

// Marco Pizzi 1,* , Francesco Piazza 2,3* Claudio Agostinelli 4 Fabio Fuligni Pietro Benvenuti 1 Elisa Mandato 2,3 Alessandro Casellato Massimo Rugge Gianpietro Semenzato and Stefano A. Pileri Department of Medicine, Surgical Pathology Cytopathology Unit, DIMED University Padua, Italy 2 Hematology Clinical Immunology Branch, 3 Venetian Institute Molecular Medicine (VIMM), Experimental, Hematopathology Sections, Diagnostic Specialty S. Orsola-Malpighi Hospital, Bologna, * These authors have contributed equally to this work Correspondence to: Piazza, email: Keywords : CK2, Non-Hodgkin Lymphoma, CX-4945, B-cell Received January 11, 2015 Accepted 28, Published 31, Abstract Serine-threonine kinase CK2 is highly expressed pivotal for survival proliferation in multiple myeloma, chronic lymphocytic leukemia mantle cell lymphoma. Here, we investigated the expression α catalytic β regulatory subunits by immunohistochemistry 57 follicular (FL), 18 Burkitt (BL), 52 diffuse large (DLBCL) non-Hodgkin lymphomas (NHL) normal reactive follicles. In silico evaluation available Gene Expression Profile (GEP) data sets from patients Western blot (WB) analysis NHL cell-lines were also performed. Moreover, novel, clinical-grade, ATP-competitive CK2-inhibitor CX-4945 (Silmitasertib) was assayed on lymphoma cells. detected 98.4% cases with a trend towards stronger CK2α immunostain BL compared FL DLBCL. No significant differences observed between Germinal Center B (GCB) non-GCB DLBCL types. GEP WB confirmed elevated mRNA protein levels as well active phosphorylation specific targets caused dose-dependent growth-arresting effect GCB, it efficiently shut off NF-κB RelA CDC37 target sites. Thus, could represent suitable therapeutic BL, NHL.